Hon Dr David Clark
Hon Dr David Clark is the Minster of Health. He was first elected as the Labour Member of Parliament for Dunedin North in 2011. He came to Parliament via a circuitous route – having run a University of Otago residential College, worked as a Presbyterian Minister, and worked as a Treasury analyst.
One of the key reasons David stood for Parliament was because he was concerned about the growing gap between rich and poor, which he sees as limiting New Zealand’s social and economic potential. Inequality featured strongly in his maiden address to the House of Representatives in 2012. He believes we can, and must, achieve a fairer society where everyone has an opportunity to succeed.
Professor Richard Sullivan
Richard Sullivan is Professor of Cancer & Global Health at Kings College London (KCL), Director, Institute of Cancer Policy. Richard qualified in medicine, and trained in surgery (urology) gaining his PhD in cell signalling from University College London. He was clinical director of Cancer Research UK between 1999 and 2008.
Following a period at the London School of Economics working on complex healthcare systems he moved to King’s College London in 2011. Richard’s research programmes focus on global cancer policy and conflict & health.
In cancer public policy he has worked on a range of global policy research programmes, including leading a Lancet Oncology Commission on Delivering Affordable Cancer Care in High Income Countries, and most recently the Lancet Commission on Global Surgery 2030, Lancet Series on Women’s Equity, Health and Cancer and the Lancet Oncology Commission on Global Cancer Surgery.
Mr Rami Rahal
Rami Rahal is the Executive Director, Cancer Control at Canadian Partnership Against Cancer In Toronto Canada. He leads the team that is responsible for researching, developing, analyzing and reporting on a broad range of system performance indicators and the production of a series of cancer-related national reports and studies.
Mr Rahal has more than 20 years of experience helping healthcare organizations and governments make informed decisions in management, policy, and planning. He combines expertise in healthcare management information and evidence-based decision support, with particular interest in cancer system performance measurement. He has led a number of workshops and courses on system performance measurement and evidence based policy at both the national and international levels.
Professor David Currow
Professor David Currow is the Chief Cancer Officer, NSW and Chief Executive Officer, Cancer Institute NSW, the NSW Government’s cancer control agency. He was appointed to the position in March 2010. Before that he was the foundation Chief Executive Officer of Cancer Australia, the Commonwealth’s cancer control agency.
He leads a team whose expertise and remit include prevention (tobacco control, ultraviolet light protection), screening (BreastScreen, Cervical Screening and Bowel Screening), service performance and development (including the population based cancer registry, Australia’s only population-based clinical cancer registry), eviQ – the world’s major evidence-based protocol website in oncology, and Canrefer, linking general practitioners and consumers with multidisciplinary teams in two clicks of a button), and strategic research and investment. The role of the Cancer Institute NSW is to decrease the incidence of cancer, increase the survival for people who are diagnosed with cancer and improve the quality of care for people with cancer.
Dr Fatima Cardoso
Dr Fatima Cardoso is the Director of the Breast Unit of the Champalimaud Clinical Center in Lisbon, Portugal. Dr Cardoso earned her medical degree at the University of Porto in Portugal and completed fellowships in the Translational Research Unit of the Jules Bordet Institute (IJB) in Brussels, Belgium, and the Department of Molecular and Cellular Oncology at MD Anderson Cancer Center in Houston, Texas. She then worked for 10 years as Assistant Professor at the Medical Oncology Clinic of the IJB where, besides her clinical work, she was active in the Translational Research Unit and was responsible for phase II-III trials in breast cancer. She is board certified in medical oncology and internal medicine.
Dr Cardoso’s research interests include biology of breast cancer, prognostic and predictive markers of response to systemic therapy, and new anticancer agents.
She is actively involved in a number of phase I-III breast cancer clinical trials and served as the scientific director of the international research network TRANSBIG for 7 years (EU Framework VI).
She is actively involved in numerous professional organizations such as ESMO, EORTC, ASCO, and AACR where she serves on several committees; she is a member of ESMO Board of Directors, member of the ESMO Public Policy Steering Committee and ESMO Guidelines Steering Committee, Past Chair of the EORTC-Breast Cancer Group, member of the ASCO Breast Cancer Guideline Advisory Group. She is also the Breast Cancer Program Coordinator of the European School of Oncology and chair of the Advanced Breast Cancer International Consensus Guidelines Conference (ABC) and of the ABC Global Alliance.
Dr Cardoso is editor-in-chief of The Breast Journal, associate editor of the European Journal of Cancer, and an editorial board member of several other journals.
She has received several educational and research grants from the Breast Cancer Research Foundation, the European Society of Medical Oncology, the European Cancer Organization, the Portuguese Science and Technology Foundation, the Portuguese League Against Cancer, the Portuguese Ministry of Health, the Free University of Brussels, the "Fonds Jean-Claude Heuson", the Fondation Lambeau-Marteau, the Belgian Federation Against Cancer, the Susan G. Komen Foundation, and the European Union Framework VI Programme.
She was awarded the prestigious Order of Santiago da Espada for Scientific Merit, from the President of Portugal, on June 10th 2015.
Dr Cardoso has authored about 280 publications and has presented her work nationally and internationally.
Dr Ashley Bloomfield
Dr Bloomfield is the Director General of Health of New Zealand. He is a public Health Physician by training. Prior to his current role he was acting chief executive for Capital & Coast District Health Board, and chief executive of the Hutt Valley District Health Board - the first clinician to hold this position. Dr Bloomfield has also held a number of senior leadership roles within the Ministry of Health, including, in 2012, acting deputy director-general, sector capability and implementation. Dr Bloomfield was partnerships advisor, Non-Communicable Diseases and Mental Health at the World Health Organization, Geneva in 2010-2011. He obtained a Bachelor of Medicine and Bachelor of Surgery at the University of Auckland in 1990.
Professor Diana Sarfati
Professor Diana Sarfati (MBChB, MPH, PhD, FNZCPHM) is a public health physician, cancer epidemiologist and health services researcher. She is Head of the Department of Public Health and the Director of the Cancer and Chronic Conditions (C3) Research Group at University of Otago, Wellington. She is currently a member of the New Zealand National Cancer Leadership Board (NZ), the Advisory Committee to International Agency for Research on Cancer’s (IARC) Pacific cancer hub, the Academic Advisory Committee to IARC on the International Cancer Benchmarking Project, and she is currently leading a Lancet Oncology series on cancer in small island developing states.
Professor John Potter
John D Potter is Professor at Massey Centre for Public Health Research and Chief Science Advisor, MoH; and Senior Advisor, Fred Hutchinson Cancer Research Center and Professor Emeritus of Epidemiology, University of Washington, both in Seattle, USA. His career is focussed on nutrition, other environmental and host factors, and genetics in the aetiology, pathobiology, and early detection of cancers and other chronic diseases. This has recently broadened to planetary health, especially in relation to diet and environmental degradation. International recognition includes AACR Award for Research Excellence in Cancer Epidemiology and Prevention (2009) and the 2012 Medal of Honour of the International Agency for Research on Cancer. He is author/co-author of more than 700 scientific papers, chapters, and books; his Scopus h-Index is 112.
Dr Nina Scott
Nina Scott, Ngapuhi, Ngati Whatua, Waikato, is a Public Health Physician and has been involved in a range of Maori cancer governance, research and advisory groups. In the past, Nina worked for the National Screening Unit where she developed and implemented comprehensive monitoring indicators for breast cancer treatment and was an inaugural member of the National Screening Unit Maori Advisory Group. Nina is chair of Hei Paa Harakeke, the Midland Maori leadership group and Hei Ahuru Mowai, the National Maori Cancer Leadership Group.
Hon Steve Maharey
Hon Steve Maharey is the Chair of the Pharmaceutical Management Agency (Pharmac). Mr Maharey was Member of Parliament for Palmerston North (1990-2008) and a Snr Minister in the New Zealand Government (1999-2008). Subsequently he was Vice-Chancellor of Massey University based in Palmerston North, Albany (Auckland) and Wellington (2008-2016). Prior to those roles Mr Maharey was an academic with interests in the development of New Zealand sociology, organisational change, cultural studies and media studies. His current areas of interest include government and the public sector, regional development, food systems, social policy, education, social change, Asia, leadership and politics. He was appointed a Companion of the New Zealand Order of Merit (CNZM) in 2008.
Dr John McMenamin
Dr John McMenamin MB ChB FRNZCGP MD is a GP involved in cancer screening and delivery in primary care. John has represented RNZCGP on the National Bowel Cancer Working Group and the Prostate Cancer Working Group, and is the GP and Primary Care lead for the National Bowel Screening Programme. John is Primary Care Adviser on Tobacco to MOH and as national Tobacco Target champion has been involved in Primary Care and Stop Smoking Service delivery of smoking cessation. John completed his MD thesis on Screening for Alcohol in General Practice and is Primary Care adviser on Alcohol to the Health Promotion Agency.
Dr Richard Sullivan
Richard Sullivan is the Deputy Chief Medical Officer at Auckland Hospital, Director Cancer and Blood Directorate, Director Cancer Outcomes Auckland District Health Board and the Director of the Northern Cancer Network. He is Medical Director at Canopy Cancer Care and the current Chair of the National Adolescent and Young Adult Cancer Network. Richard completed his medical training at the University of Otago and was awarded FRACP in 2004. He works as a Medical Oncologist and is Principal investigator in many clinical trials in his area of expertise - Lung Cancer and Mesothelioma.
Professor Kathryn McPherson
Professor Kathryn McPherson became the Chief Executive of the HRC in 2015 (www.hrc.govt.nz). Shortly after her appointment, the government announced a ‘strategic refresh’ of the HRC and this resulted in a 56% increase in investment over four years with the last year of that increase to be allocated in 2019. Kath is now working with colleagues at Ministry of Health and the Ministry of Business, Innovation and Employment to implement NZ’s first Health Research Strategy.
Kath has a background as a health professional (as a nurse and midwife) and an academic background in psychology and rehabilitation. Her own research predominately focuses on new approaches to improving outcome, and quality of healthcare for people with long term disabling health conditions (including cancer although most in neurorehabilitation).
Kath is author or co-author of more than 200 peer-reviewed journal articles and holds a PhD from the University of Edinburgh.
Kath’s most recent academic appointments have been at AUT University (NZ) where she is Adjunct Professor, and previously at the University of Southampton (UK) and the University of Otago Wellington (NZ). Kath maintains an active involvement in research and publication although at a reduced level in view of her current appointment.
Professor Parry Guilford
Professor Parry Guilford is Director of the Cancer Genetics Laboratory and the Centre for Translational Cancer Research (Te Aho Matatū) at the University of Otago. He is a co-founder of the publically listed biotechnology company Pacific Edge Ltd and a Deputy Director of the Healthier Lives National Science Challenge. His current research interests include the genetics of inherited and sporadic cancers, in particular stomach cancer. Other active research areas are the development of genomic-based diagnostic tools for early cancer detection and personalised medicine.
Professor Ian Bissett
Ian Bissett is Professor and Head of Surgery at the University of Auckland and Consultant Colorectal Surgeon at Auckland City Hospital. He graduated in 1979 from the University of Auckland and completed his FRACS in 1987 and then worked as a general surgeon in Pokhara, Nepal until 1997. He then undertook his MD research in the anatomy and radiology of rectal cancer. In 2001 he spent a year in the Colorectal Unit in Concord Hospital in Sydney then returned to his present position. He served as President of the Coloectal Surgical Society of Australia and NZ from 2011-2013 and is the chair of the Narional Bowel Cancer Working Group and the adult clinical director of the National Intestinal Failure Service in NZ. His particular interests include rectal cancer, the assessment and management of defaecatory disorders, gut motility and Global Surgery. He has over 100 publications in peer reviewed journals and 5 book chapters published. He continues to visit Nepal on a yearly basis to perform outreach surgical clinics and teach. He is married to Johanna and has 3 children and 2 grandchildren.
Dr Christopher Jackson
Dr Christopher Jackson is medical director of the Cancer Society of NZ, as well as a medical oncologist at Southern DHB and senior lecturer in medicine at the University of Otago. Clinically, his interests are in GI cancers and melanoma. He is currently chair of the Bowel Cancer tumour standards group, a member of the national bowel cancer work group, and clinical lead for oncology research at Southern DHB. As medical director of the Cancer Society, Chris has been a vocal advocate for a joined-up national approach to cancer policy and for many changes in cancer policy across the cancer control continuum.
Ms Shelley Campbell
Shelley (Ngati Hine) is currently the CEO of the Waikato Bay of Plenty Cancer Society providing cancer prevention and support services to over 700 000 people in the region. She leads the team of 800 staff and volunteers working to prevent and minimise the impact of cancer through health promotion, research and community services including the Cancer Society Lions Lodge, Outreach Nursing and transport services. With over 20 years experience working in Health, Shelley has received a Blake Leadership Award for her work in Primary care and in 2017 was awarded a MNZM for her work in the health and disability sector.
Shelley is a life member of the Halberg Foundation, Board member of Enrich, Te Pou, and LeVa and in 2017 was appointed to NIWA’s National Science Challenge Board. In 2018 she was appointed to the Health Review Panel. She mentors emerging CEOs across New Zealand and teaches on the National Maori health leadership programme.
Dr Jason Gurney
Dr Jason Gurney is an epidemiologist and Māori health researcher from the Department of Public Health, University of Otago, Wellington. He is the Deputy Director of the Cancer and Chronic Conditions (C3) Research Group, and a board member of Hei Āhuru Mōwai (the National Māori Cancer Leadership Group). Jason’s research focusses on understanding the drivers of health inequites between Māori and non-Māori New Zealanders, particularly in the context of cancer. Among other projects, he is leading a national case-control study which is trying to explain why Māori experience the greatest rates of testicular cancer in New Zealand. He has also recently been awarded a four-year HRC Māori Emerging Leader Fellowship, to complete a programme of work which aims to improve the quantity and quality of life for Māori with cancer.
Dr Jonathan Adler
Dr Jonathan Adler is a Palliative Medicine Physician who dual trained in the UK and Australasia. He is the Clinical Lead for Palliative Care at Wellington Regional Hospital CCDHB, and also a Senior Clinical Lecturer at the Wellington School of Medicine, University of Otago. Jonathan’s areas of interest include patient centered communication, symptom control, ethics at the end of life, advance care planning and goals of care, and prognostication.
Dr Jane O’Hallahan
Dr Jane O’Hallahan (Public Health Medicine Specialist) has been the Clinical Director of the Cancer Screening (bowel, cervical, breast) and Antenatal Screening Programmes (Down syndrome and other conditions, metabolic, hearing) for the past 5 years with the National Screening Unit, Ministry of Health in New Zealand.
During this time the main achievements of the National Screening Unit include development of a Quality Framework; management of a major hearing incident; introduction of a National Bowel Cancer Screening Programme; improvement in equity in the Breast Screening Programme and development of an open disclosure policy.
Jane has led the work with the National Screening Advisory Committee considering new screening programmes and major changes to existing programmes and the Maori Monitoring and Equity Group which provides advice on equity.
Prior to this Jane has worked as a Medical Officer of Health and Clinical Director of the Meningococcal Vaccine Programme whereby an orphan vaccine was developed to combat an epidemic of a strain of Group B meningococcal disease.
Dr Caroline Shaw
Dr Caroline Shaw (MBChB, MPH, PhD, FNZCPHM) is a public health physician and epidemiologist. She has a long standing interest in population screening, having previously working at the National Screening Unit on a wide range of screening issues, including colorectal cancer screening and screening equity. She has been a member of the National Screening Advisory Committee since 2009 and co-convenes the highly regarded Population Screening Summer School course at the University of Otago Summer School. She teaches population screening in a wide range of health professional courses and regards it as simultaneously one of the most interesting and most poorly understood areas of health practice.
Dr Karyn Paringatai
Dr Karyn Paringatai (Ngāti Porou) is a Senior Lecturer in Te Tumu – School of Māori, Pacific and Indigenous Studies, University of Otago where she teaches primarily in the area of Māori language acquisition and Māori cultural knowledge. Her research focuses primarily on Māori performing arts traditions and sociological aspects of Māori experience including Māori urbanisation, Māori identity development and maintenance and the multiple dimensions of whakapapa. She is a co-director of Poutama Ara Rau, an Otago Research Theme that is committed to drawing upon Māori knowledge traditions and pedagogies to transform teaching and learning in the university setting.
Dr Ben Lawrence
Dr Ben Lawrence is a Medical Oncologist who treats gastrointestinal cancers and neuroendocrine tumours (NETs). He trained at the three Auckland Hospitals, the Translational Genomics Institute in Arizona, and Yale University. He co-directs an integrated research and clinical programme called NETwork! with Professor Cris Print as a translational partner. The Network! team undertake multi-level tumour sequencing of NETs looking for predictive biomarkers informed by genomics. Dr Lawrence is the immediate past-President of the New Zealand Society for Oncology. He collaborates with cancer researchers in Australia, USA, and Europe, and is Principal Investigator on several multinational and collaborative group trials. His clinical and research work explores precision medicine in cancer care.
Ms Stephanie Turner
Stephanie Turner (Ko Ngāti Raukawa te Iwi; Ko Ōtaki te Turangawaewae) is an Executive Member of Hei Āhuru Mōwai - Māori Cancer Leadership Aotearoa and GM of Maori Health MidCentral District Health Board. She has an MA with honors in Art Therapy. Stephanie is committed to developing policies, operational systems, programmes and services that honor Te Tiriti o Waitangi and supports the advancement of Maori concepts within healthcare. Stephanie works with people to raise awareness and understanding of Maori worldview; values, beliefs and knowledge to support the integration of Maori ideas within health system development, structures and practice. She uses Matauranga Maori (Cosmo Genealogy) & Pu Rakau (knowledge & stories passed down) offer insights and strategic ideas that can be applied across different organizational settings and delivery.
Dr Shaun Costello
Since completing training at the Royal Free Hospital, London Dr Costello first went to Aberdeen to study for the MRCP. After achieving the exam in 1986 he moved to Glas-gow to train in Clinical Oncology. He qualified in 1990 with the FRCR picking up an MSc in Medical and Clinical Oncology on the way.
Shaun spent a year in Christchurch Hospital New Zealand and was appointed Consultant in Oncology at Dunedin Hospital in 1992. He was involved in developing and directing the National Stereotactic Radiosurgery Service in 1994.
In 2001 he was recruited to Ontario Canada as Medical Director for the new cancer cen-tre in Grand River, which opened July 2003. In 2002, he became fellow of the Canadian College (FRCPC) and an Assoc Prof of the University of Ontario.
He was re recruited to Dunedin in September 2003 to work in the Oncology Service, in December 2003 he was appointed Director of Medical Services for Healthcare Otago, and was also appointed as the Clinical Director of the Southern Cancer Network. He re-signed as Medical Director for the District Health Board but remains the CD of the Can-cer Network and the Medical Director of Radiation Oncology.
He has an interest in the application of technology to cancer care and most recently was involved in the team creating the Radiation Oncology Collection, the most comprehen-sive data collection of patients receiving radiation for the treatment of cancer.